1. Epstein-Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV.
- Author
-
Venturini C, Houldcroft CJ, Lazareva A, Wegner F, Morfopoulou S, Amrolia PJ, Golwala Z, Rao A, Marks SD, Simmonds J, Yoshikawa T, Farrell PJ, Cohen JI, Worth AJ, and Breuer J
- Subjects
- Adolescent, Biomarkers analysis, Case-Control Studies, Child, Child, Preschool, Chronic Disease, Defective Viruses genetics, Epstein-Barr Virus Infections drug therapy, Epstein-Barr Virus Infections epidemiology, Asia, Eastern epidemiology, Female, Humans, Immunologic Factors therapeutic use, Male, Peripheral Blood Stem Cell Transplantation methods, Polymorphism, Single Nucleotide genetics, Rituximab therapeutic use, Treatment Outcome, Virus Replication genetics, Epstein-Barr Virus Infections blood, Herpesvirus 4, Human genetics, Saliva metabolism, Sequence Deletion genetics
- Abstract
Chronic active Epstein-Barr virus (CAEBV) disease is a rare condition characterised by persistent EBV infection in previously healthy individuals. Defective EBV genomes were found in East Asian patients with CAEBV. In the present study, we sequenced 14 blood EBV samples from three UK patients with CAEBV, comparing the results with saliva CAEBV samples and other conditions. We observed EBV deletions in blood, some of which may disrupt viral replication, but not saliva in CAEBV. Deletions were lost overtime after successful treatment. These findings are compatible with CAEBV being associated with the evolution and persistence of EBV
+ haematological clones that are lost on successful treatment., (© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)- Published
- 2021
- Full Text
- View/download PDF